Replimune Reaches Agreement With FDA to Resubmit Melanoma Drug Application

What’s happening

Replimune Group reached an agreement with the FDA on a path to resubmit its melanoma drug application after previous regulatory setbacks.

The company is working to address concerns raised during the review process.

What’s changing / Business impact

The agreement gives the company another opportunity to seek approval and potentially bring the treatment to market.

Why this matters

Melanoma is one of the most serious forms of skin cancer, and companies often spend years and hundreds of millions of dollars developing treatments.